Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:ELYM NASDAQ:MGX NASDAQ:SYBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$2.68-2.5%$3.11$0.40▼$5.48$64.74M0.27104,576 shs65,255 shsELYMEliem Therapeutics$2.38-3.6%$1.77$2.35▼$11.55$70.81M-0.39486,688 shs254,085 shsMGXMetagenomi$1.84-1.1%$2.02$1.23▼$4.92$69.81M-0.17204,542 shs101,376 shsSYBXSynlogic$1.50+2.7%$1.45$0.90▼$1.96$17.08M0.5419,335 shs31,438 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+1.10%+0.73%+1.85%+64.67%+323.79%ELYMEliem Therapeutics+3.35%+10.76%+45.29%+80.29%-68.45%MGXMetagenomi0.00%+2.20%-3.12%+24.83%-35.86%SYBXSynlogic+0.68%+1.37%+5.71%+21.31%+0.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$2.68-2.5%$3.11$0.40▼$5.48$64.74M0.27104,576 shs65,255 shsELYMEliem Therapeutics$2.38-3.6%$1.77$2.35▼$11.55$70.81M-0.39486,688 shs254,085 shsMGXMetagenomi$1.84-1.1%$2.02$1.23▼$4.92$69.81M-0.17204,542 shs101,376 shsSYBXSynlogic$1.50+2.7%$1.45$0.90▼$1.96$17.08M0.5419,335 shs31,438 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+1.10%+0.73%+1.85%+64.67%+323.79%ELYMEliem Therapeutics+3.35%+10.76%+45.29%+80.29%-68.45%MGXMetagenomi0.00%+2.20%-3.12%+24.83%-35.86%SYBXSynlogic+0.68%+1.37%+5.71%+21.31%+0.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/AELYMEliem Therapeutics 0.00N/AN/AN/AMGXMetagenomi 3.00Buy$10.00443.48% UpsideSYBXSynlogic 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SYBX, ABVC, ELYM, and MGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025MGXMetagenomiHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/15/2025MGXMetagenomiChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.008/14/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$16.00 ➝ $12.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K123.70N/AN/A$0.06 per share44.67ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AMGXMetagenomi$52.29M1.32N/AN/A$6.28 per share0.29SYBXSynlogic$10K1,755.00N/AN/A$1.09 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$4.90M-$0.17N/A∞N/A-963.46%-46.76%-23.02%11/12/2025 (Estimated)ELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AMGXMetagenomi-$78.06M-$2.36N/AN/AN/A-257.99%-37.84%-27.15%11/12/2025 (Estimated)SYBXSynlogic-$23.36M-$0.08N/AN/AN/AN/A-8.09%-5.50%11/11/2025 (Estimated)Latest SYBX, ABVC, ELYM, and MGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ABVCABVC BioPharmaN/A-$0.13N/A-$0.13N/AN/A8/12/2025Q2 2025MGXMetagenomi-$0.68-$0.54+$0.14-$0.54$7.72 million$8.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/ASYBXSynlogicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.420.42ELYMEliem TherapeuticsN/A60.4160.41MGXMetagenomiN/A6.366.36SYBXSynlogicN/A3.633.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%ELYMEliem Therapeutics69.76%MGXMetagenomiN/ASYBXSynlogic63.40%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%ELYMEliem Therapeutics4.70%MGXMetagenomi17.80%SYBXSynlogic3.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3023.54 million19.52 millionNot OptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableMGXMetagenomi23637.53 million30.85 millionN/ASYBXSynlogic8011.70 million11.35 millionOptionableSYBX, ABVC, ELYM, and MGX HeadlinesRecent News About These CompaniesSynlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo FinanceJune 28, 2025 | finance.yahoo.comSynlogic's executive sells shares worth $2,802February 5, 2025 | msn.comSynlogic Reports Q3 2024 Financial OutcomesNovember 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSynlogic Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comSynlogic preps phenylketonuria drug for phase 3 after mid-stage winNovember 6, 2024 | pharmaphorum.comPSynlogic, Inc. (0A8U.L)August 24, 2024 | nz.finance.yahoo.comMIN.SG,0P0001I7V6,0 (MIN.SG)August 16, 2024 | nz.finance.yahoo.comMaintaining Hold on Synlogic Amid Strategic Reassessment and Financial UncertaintyAugust 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deSYBX Stock Earnings: Synlogic Beats EPS for Q2 2024August 8, 2024 | investorplace.comSynlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comSynlogic Inc.July 21, 2024 | wsj.comSynlogic Inc SYBXJuly 21, 2024 | morningstar.comMThe Summer Stock Exodus: 3 Companies to Ditch Before the Heat HitsMay 23, 2024 | investorplace.comHold Rating Maintained for Synlogic Amidst Setbacks and Financial UncertaintiesMay 16, 2024 | markets.businessinsider.comSYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comSynlogic, Inc.: Synlogic Reports First Quarter 2024 Financial ResultsMay 14, 2024 | finanznachrichten.deSynlogic Flat on Q1 NumbersMay 14, 2024 | baystreet.caSynlogic Reports First Quarter 2024 Financial ResultsMay 14, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSYBX, ABVC, ELYM, and MGX Company DescriptionsABVC BioPharma NASDAQ:ABVC$2.68 -0.07 (-2.55%) Closing price 04:00 PM EasternExtended Trading$2.68 +0.00 (+0.19%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Eliem Therapeutics NASDAQ:ELYM$2.38 -0.09 (-3.64%) As of 09/9/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Metagenomi NASDAQ:MGX$1.84 -0.02 (-1.08%) Closing price 04:00 PM EasternExtended Trading$1.89 +0.05 (+2.93%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Synlogic NASDAQ:SYBX$1.50 +0.04 (+2.74%) Closing price 03:49 PM EasternExtended Trading$1.50 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
